TY  - GEN
AU  - Steiner,Israel
TI  - Quantitative risk-benefit analysis of natalizumab
SN  - 1526-632X
PY  - 2009///0601
KW  - Antibodies, Monoclonal
KW  - adverse effects
KW  - Antibodies, Monoclonal, Humanized
KW  - Clinical Trials as Topic
KW  - Humans
KW  - Leukoencephalopathy, Progressive Multifocal
KW  - etiology
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - complications
KW  - Natalizumab
KW  - Risk Factors
N1  - Publication Type: Comment; Letter
UR  - https://doi.org/10.1212/01.wnl.0000347020.85704.36
ER  -